Business Context and Reporting Period
The filing is Aeglea BioTherapeutics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2016. The requested company name is Spyre Therapeutics, Inc.; the filing text identifies the registrant as Aeglea BioTherapeutics, Inc., so the entity and historical name should be verified.
Aeglea was an early-stage biotechnology company developing engineered enzyme therapeutics for amino-acid metabolism. Its lead candidate, AEB1102, targeted Arginase I deficiency and arginine-dependent cancers. The company had no product revenue and operated in a single segment.
Financial Performance and Position
| Metric | Q1 2016 | Q1 2015 | Change |
|---|---|---|---|
| Grant revenue | $0.9 million | $0 | $0.9 million increase |
| Research and development expense | $3.6 million | $1.6 million | 122% increase |
| General and administrative expense | $1.8 million | $0.8 million | 116% increase |
| Total operating expenses | $5.4 million | $2.5 million | 120% increase |
| Loss from operations | $4.6 million | $2.5 million | 85% increase in loss |
| Net loss | $4.5 million | $2.5 million | 84% increase in loss |
| Net loss attributable to common stockholders | $4.5 million | $2.7 million | 77% decrease in amount of loss |
| Basic and diluted loss per share | $7.10 | $4.71 | Greater loss per share |
| Net cash used in operating activities | $4.0 million | $2.5 million | $1.5 million increase in use |
| Net decrease in cash | $5.3 million | Net increase of $41.2 million | Unfavorable change |
Revenue consisted solely of reimbursements under a $19.8 million CPRIT research grant covering June 2014 through May 2017. The grant receivable was $1.6 million at March 31, 2016.
At March 31, 2016, cash and cash equivalents were $24.0 million, marketable securities were $5.0 million, and total cash, cash equivalents and marketable securities were $29.0 million. Working capital was $31.4 million. Total assets were $35.5 million, total liabilities were $3.8 million, and accumulated deficit was $28.1 million.
The company reported no debt or debt facility. Convertible preferred stock totaled $58.3 million and was classified as temporary equity before its subsequent conversion in connection with the IPO. Stock-based compensation expense was $0.1 million.
Research and development spending increased primarily because of higher toxicology and nonclinical study costs, increased personnel, and preparation for or initiation of Phase 1 trials. AEB1102-related spending increased to $2.4 million from $0.9 million.
Material Changes Versus the Prior Comparable Period
- Grant revenue began in 2016 because the CPRIT grant agreement was executed in June 2015; there was no grant revenue in Q1 2015.
- Research and development expense increased $2.0 million, or 122%, as AEB1102 advanced toward additional clinical trials.
- General and administrative expense increased $1.0 million, primarily from personnel, recruiting, professional services, audit and legal costs associated with becoming a public company.
- Operating cash use increased to $4.0 million from $2.5 million.
- Q1 2015 cash flow benefited from $43.7 million of Series B preferred-stock financing; there was no comparable financing in Q1 2016.
- The company completed a 1-for-10.5 reverse stock split effective March 28, 2016. Share and per-share data were retrospectively adjusted.
Guidance, Outlook, Risks and Unusual Items
In April 2016, after the reporting date, the company completed an IPO of 5,481,940 common shares at $10.00 per share and received approximately $47.3 million of net proceeds. Outstanding preferred stock automatically converted into 7,172,496 common shares immediately before the IPO.
Management expected to use available funds and IPO proceeds to continue clinical trials of AEB1102 in solid tumors, hematological malignancies and Arginase I deficiency, and to advance at least one additional product candidate. Management stated that these resources were expected to fund operations through at least March 31, 2018, although actual spending could be faster than projected.
The FDA had declared effective the AEB1102 INDs for hematological malignancies and Arginase I deficiency. Management intended to initiate Phase 1 dose-escalation studies in the first half of 2016. A Canadian CTA for the hematological malignancy trial was declared effective in April 2016.
The company expected continuing and increasing losses because it had no approved products, no product sales, and substantial clinical, manufacturing, regulatory and public-company costs. Additional financing would be required to complete all planned development activities. No additional committed capital was in place.
- Key risks included clinical-trial failure or delay, patient-enrollment challenges, adverse events, regulatory nonapproval, manufacturing dependence on third parties, competition, intellectual-property challenges, and the need for additional capital.
- The CPRIT agreement could require low- to mid-single-digit royalties on certain future product or license revenues, reducing to less than 1% after repayment of a multiple of grant funding.
- University license agreements could require up to $6.4 million of milestone payments per product candidate, annual license fees, and low-single-digit royalties on future net sales.
- The company disclosed six serious adverse events in four patients in the solid-tumor trial; management assessed none as related to trial therapy. One patient died after discontinuing the trial because of worsening underlying cancer.
- The company disclosed related-party consulting payments of $129,000 to the CEO’s spouse during Q1 2016 and $13,000 to a founder-director.
- No material legal proceedings were pending, and the company reported no off-balance-sheet arrangements.
- Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level, with no material changes in internal control over financial reporting during the quarter.
Important Facts for Investors to Verify
- Confirm whether this historical Aeglea filing is the intended filing for Spyre Therapeutics, Inc., including any corporate name changes or successor relationships.
- Verify the post-quarter IPO proceeds, conversion of preferred stock, post-IPO share count and resulting dilution.
- Assess cash runway against the company’s stated March 31, 2018 funding horizon and its expectation of increasing research and development spending.
- Track clinical initiation, enrollment, safety and efficacy results for AEB1102 across the three planned indications.
- Monitor CPRIT grant reimbursement, remaining grant availability, future royalty obligations and any conditions affecting collection.
- Review the contingent university milestone payments, license termination provisions and future royalty exposure.
- Evaluate the effect of no product revenue, recurring operating losses and the company’s dependence on future financing or collaboration revenue.